Meeting
2022 ASCO Annual Meeting
A retrospective analysis of patients administered neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin with oral metronomic chemotherapy (OMCT) in locally advanced borderline resectable/technically unresectable head and neck cancers.
Authors
Shruti Pathak
Tata Memorial Centre, Mumbai, India
Shruti Pathak , Zoya Peelay , Vijay Maruti Patil , Nandini Sharrel Menon , Pankaj Chaturvedi , Kumar Prabhash , Vanita Noronha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6030)
DOI
10.1200/JCO.2022.40.16_suppl.6030
Abstract #
6030
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT).
First Author: Sunil Ramdhan Chopade
First Author: Akhil Kapoor
Poster
2022 ASCO Annual Meeting
Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.
First Author: Ajaykumar Singh
Poster
2022 ASCO Annual Meeting
Phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.
First Author: Vijay Maruti Patil